MX2020012217A - Porción de unión para activación condicional de moléculas de inmunoglobulina. - Google Patents
Porción de unión para activación condicional de moléculas de inmunoglobulina.Info
- Publication number
- MX2020012217A MX2020012217A MX2020012217A MX2020012217A MX2020012217A MX 2020012217 A MX2020012217 A MX 2020012217A MX 2020012217 A MX2020012217 A MX 2020012217A MX 2020012217 A MX2020012217 A MX 2020012217A MX 2020012217 A MX2020012217 A MX 2020012217A
- Authority
- MX
- Mexico
- Prior art keywords
- binding
- binding moiety
- immunoglobulin molecules
- conditional activation
- proteins
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se describen en la presente porciones de unión que comprenden bucles no de CDR para enmascarar la unión de una molécula de unión a su objetivo y CDRs para unir las proteínas de suero a granel. También se proporcionan proteínas de unión objetivo condicionalmente activas que contienen las porciones de unión. Se proporcionan además composiciones farmacéuticas que comprenden las proteínas de unión descritas en la presente y métodos para utilizar estas formulaciones.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862671344P | 2018-05-14 | 2018-05-14 | |
US201862671349P | 2018-05-14 | 2018-05-14 | |
US201862756453P | 2018-11-06 | 2018-11-06 | |
US201862756429P | 2018-11-06 | 2018-11-06 | |
PCT/US2019/032307 WO2019222283A1 (en) | 2018-05-14 | 2019-05-14 | Binding moiety for conditional activation of immunoglobulin molecules |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020012217A true MX2020012217A (es) | 2021-03-02 |
Family
ID=68540678
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020012217A MX2020012217A (es) | 2018-05-14 | 2019-05-14 | Porción de unión para activación condicional de moléculas de inmunoglobulina. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20210292421A1 (es) |
EP (1) | EP3794038A4 (es) |
JP (1) | JP2021523192A (es) |
KR (1) | KR20210020903A (es) |
CN (1) | CN112513083A (es) |
AU (1) | AU2019271138A1 (es) |
BR (1) | BR112020023330A2 (es) |
CA (1) | CA3100327A1 (es) |
MX (1) | MX2020012217A (es) |
SG (1) | SG11202011330PA (es) |
WO (1) | WO2019222283A1 (es) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2016263808B2 (en) | 2015-05-21 | 2019-01-03 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
KR102530742B1 (ko) | 2016-05-20 | 2023-05-09 | 하푼 테라퓨틱스, 인크. | 단일 도메인 혈청 알부민 결합 단백질 |
AU2017363302A1 (en) | 2016-11-23 | 2019-06-27 | Harpoon Therapeutics, Inc. | PSMA targeting trispecific proteins and methods of use |
KR20210087108A (ko) | 2016-11-23 | 2021-07-09 | 하푼 테라퓨틱스, 인크. | 전립선 특이 막 항원 결합 단백질 |
EP3589662A4 (en) | 2017-02-28 | 2020-12-30 | Harpoon Therapeutics, Inc. | INDUCTIBLE MONOVALENT ANTIGBINDING PROTEIN |
BR112019023856A2 (pt) | 2017-05-12 | 2020-06-09 | Harpoon Therapeutics Inc | proteínas triespecíficas que visam msln e métodos de utilização |
EP3621994A4 (en) | 2017-05-12 | 2020-12-30 | Harpoon Therapeutics, Inc. | MESOTHELINE BINDING PROTEINS |
IL302613A (en) | 2017-09-08 | 2023-07-01 | Maverick Therapeutics Inc | Binding proteins are activated under limited conditions |
BR112020007196A2 (pt) | 2017-10-13 | 2020-12-01 | Harpoon Therapeutics, Inc. | proteínas triespecíficas e métodos de uso |
BR112020007249B1 (pt) | 2017-10-13 | 2022-11-22 | Harpoon Therapeutics, Inc | Roteína de ligação a antígeno de maturação de célula b, proteína de ligação multiespecífica e uso das referidas proteínas |
AU2019346466A1 (en) | 2018-09-25 | 2021-05-20 | Harpoon Therapeutics, Inc. | DLL3 binding proteins and methods of use |
WO2020181140A1 (en) * | 2019-03-05 | 2020-09-10 | Maverick Therapeutics, Inc. | Constrained conditionally activated binding proteins |
CN114173876A (zh) * | 2019-03-05 | 2022-03-11 | 武田药品工业有限公司 | 含有靶向肿瘤抗原的Fc区和部分的条件性活化的结合蛋白质 |
WO2021097060A1 (en) * | 2019-11-13 | 2021-05-20 | Harpoon Therapeutics, Inc. | Pro immune modulating molecule comprising a clustering moiety |
CA3170833A1 (en) | 2020-02-21 | 2021-08-26 | Harpoon Therapeutics, Inc. | Flt3 binding proteins and methods of use |
EP4186928A1 (en) * | 2020-07-08 | 2023-05-31 | Nanjing Normal University | Fusion polypeptide and polypeptide dimer, and use thereof |
CN113912735A (zh) * | 2020-07-08 | 2022-01-11 | 南京师范大学 | 多肽二聚体及其用途 |
WO2022098909A1 (en) * | 2020-11-06 | 2022-05-12 | Harpoon Therapeutics, Inc. | Epcam targeting trispecific protein for treatment of cancer |
IL302597A (en) * | 2020-11-06 | 2023-07-01 | Amgen Inc | Constructive polypeptide binds to CD3 |
CA3224137A1 (en) * | 2021-06-25 | 2022-12-29 | Holger Wesche | Extended-release immune cell engaging proteins and methods of treatment |
WO2023064945A2 (en) * | 2021-10-15 | 2023-04-20 | Harpoon Therapeutics, Inc. | Conditional activation of immunoglobulin molecules |
WO2023104190A1 (en) * | 2021-12-09 | 2023-06-15 | Vibrant Pharma Limited | Antibody masks and uses thereof |
WO2023161853A1 (en) | 2022-02-23 | 2023-08-31 | Bright Peak Therapeutics Ag | Activatable il-18 polypeptides |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2162823T5 (es) | 1992-08-21 | 2010-08-09 | Vrije Universiteit Brussel | Inmunoglobulinas desprovistas de cadenas ligeras. |
US20090298195A1 (en) * | 2005-01-05 | 2009-12-03 | F-Star Biotechnologische Forschungs-Und Entwicklun Gseges M.B.H. | Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions |
EP3492488A1 (en) * | 2007-08-22 | 2019-06-05 | The Regents of The University of California | Activatable binding polypeptides and methods of identification and use thereof |
AU2010203353B2 (en) * | 2009-01-12 | 2016-06-16 | Cytomx Therapeutics, Inc | Modified antibody compositions, methods of making and using thereof |
CN104185474B (zh) * | 2012-03-30 | 2017-08-25 | 拜尔健康护理有限责任公司 | 蛋白酶调节的抗体 |
EP3288981A1 (en) * | 2015-05-01 | 2018-03-07 | Genentech, Inc. | Masked anti-cd3 antibodies and methods of use |
JP6841754B2 (ja) * | 2015-05-13 | 2021-03-10 | 中外製薬株式会社 | 多重抗原結合分子融合体、医薬組成物、線状エピトープの同定方法、および多重抗原結合分子融合体の製造方法 |
AU2016263808B2 (en) * | 2015-05-21 | 2019-01-03 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
DK3313874T3 (da) * | 2015-06-26 | 2021-05-03 | Univ Southern California | Maskering af kimære antigen-receptor t-celler til tumorspecifik aktivering |
TW202302631A (zh) * | 2016-03-08 | 2023-01-16 | 日商武田藥品工業股份有限公司 | 可誘導性結合蛋白和使用方法 |
WO2017161206A1 (en) * | 2016-03-16 | 2017-09-21 | Halozyme, Inc. | Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use |
PE20181891A1 (es) * | 2016-03-22 | 2018-12-11 | Hoffmann La Roche | Moleculas biespecificas de celulas t activadas por proteasas |
KR102530742B1 (ko) * | 2016-05-20 | 2023-05-09 | 하푼 테라퓨틱스, 인크. | 단일 도메인 혈청 알부민 결합 단백질 |
-
2019
- 2019-05-14 AU AU2019271138A patent/AU2019271138A1/en active Pending
- 2019-05-14 JP JP2020564068A patent/JP2021523192A/ja active Pending
- 2019-05-14 CN CN201980047378.8A patent/CN112513083A/zh active Pending
- 2019-05-14 BR BR112020023330-7A patent/BR112020023330A2/pt unknown
- 2019-05-14 MX MX2020012217A patent/MX2020012217A/es unknown
- 2019-05-14 KR KR1020207035713A patent/KR20210020903A/ko active Search and Examination
- 2019-05-14 US US17/055,096 patent/US20210292421A1/en active Pending
- 2019-05-14 CA CA3100327A patent/CA3100327A1/en active Pending
- 2019-05-14 SG SG11202011330PA patent/SG11202011330PA/en unknown
- 2019-05-14 WO PCT/US2019/032307 patent/WO2019222283A1/en unknown
- 2019-05-14 EP EP19804053.7A patent/EP3794038A4/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3794038A1 (en) | 2021-03-24 |
EP3794038A4 (en) | 2022-02-16 |
US20210292421A1 (en) | 2021-09-23 |
CN112513083A (zh) | 2021-03-16 |
AU2019271138A1 (en) | 2021-01-07 |
JP2021523192A (ja) | 2021-09-02 |
WO2019222283A1 (en) | 2019-11-21 |
KR20210020903A (ko) | 2021-02-24 |
CA3100327A1 (en) | 2019-11-21 |
SG11202011330PA (en) | 2020-12-30 |
BR112020023330A2 (pt) | 2021-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020012217A (es) | Porción de unión para activación condicional de moléculas de inmunoglobulina. | |
IL288204A (en) | Protein-targeted compounds and their pharmaceutical preparations and their medical applications | |
BR112019003775A2 (pt) | anticorpo monoclonal anti-pd1, composição farmacêutica do mesmo e uso dos mesmos | |
MX2022014463A (es) | Construcciones de union a antigeno para moleculas diana. | |
EA201890613A1 (ru) | Полипептиды, связывающие cd3 | |
WO2016210365A3 (en) | Constructs targeting ny-eso-1 peptide/mhc complexes and uses thereof | |
MX2021000347A (es) | Inhibidores de tgf?1 selectivos de isoforma, de alta afinidad y usos de los mismos. | |
EA201290123A1 (ru) | Продукты слияния и конъюгаты лекарственных средств с увеличенным периодом полувыведения | |
MX2017014056A (es) | Construcciones dirigidas a complejos de peptido e7 del subtipo 16 del virus de papiloma humano (hpv16-e7)/complejo principal de histocompatibilidad (mhc) y sus usos. | |
WO2017060322A3 (en) | Ptefb-inhibitor-adc | |
MX2020004691A (es) | Enlazadores hidrofilicos para conjugados anticuerpo-farmaco. | |
PH12020500137A1 (en) | Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods | |
WO2016032949A8 (en) | Targeting immunotherapy for amyloidosis | |
MX2017013171A (es) | Conjugados anticuerpo-farmaco de sitio especifico. | |
WO2023064945A3 (en) | Conditional activation of immunoglobulin molecules | |
EA202091054A1 (ru) | Слитые молекулы на основе антитела против pd-l1 и ил-7 | |
EA201991912A1 (ru) | Составы, содержащие pd-1-связывающие белки, и способы их получения | |
MY194084A (en) | Interferon beta antibodies and uses thereof | |
CR20210094A (es) | ANTICUERPOS QUE SE UNEN A LA PROTEÍNA DE ENVOLTURA DEL VIRUS ZIKA Y USOS DE LOS MISMOS (Divisional 2019-0193) | |
EA201990895A1 (ru) | Антитела к о1 и варианты их применения | |
EA201500506A1 (ru) | КОНЪЮГАТЫ И МАЛЫЕ МОЛЕКУЛЫ, ВЗАИМОДЕЙСТВУЮЩИЕ С РЕЦЕПТОРОМ CD16a | |
ZA202003320B (en) | Glucuronylation as acidic post-translational modification on therapeutic monoclonal antibodies | |
WO2017015634A3 (en) | Constructs targeting psa peptide/mhc complexes and uses thereof | |
EA202190382A1 (ru) | Фармацевтические составы на основе маскированных антител | |
WO2015191590A3 (en) | Combination therapies targeting tumor-associated stroma or tumor cells and microtubules |